We are proud to announce the 14th edition of the European Meeting o HIV & Hepatitis - Treatment strategies & Antiviral Drug Resistance, preliminarily scheduled to take place on 30 May - 1 June 2016 in Rome, Italy.
This meeting was started 15 years ago with the objective to provide clinical virologists and other infectious diseases treating specialists involved in both research and clinical practice with the opportunity to share data and discuss their clinical application. The focus of the workshop at the time was specifically on HIV antiretroviral drug resistance, which was the main challenge facing the clinician a decade ago. Hence the original name as the European Drug Resistance workshop.
Over the years the challenges facing European clinicians treating HIV patients expanded. As resistance was better understood and managed, broader treatment issues (adherence, toxicity, etc.) were added to the workshop. Similarly, as better treatments for HCV became available, many of them were required to treat viral Hepatitis as well. Therefore the workshop (and its name) were expended to keep pace with the needs of the European clinicians – The European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. Although resistance is still an important feature of the meeting, the other key topics in treatment strategies are addressed – similarly although HIV remains very much a key component – treatment of Hepatitis infection is also included.
In the last decade the meeting has been able to capture a constant group of leading clinicians and researchers from Europe. The European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance is a unique European platform for clinicians and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV and HBV and for translating them into new treatment strategies to further improve clinical care.
By attending this meeting, you will receive a full overview of the latest developments in Hepatitis B, C and HIV, translated to clinical practice. The meeting will provide ample time for Q & A, discussion and interaction in a balanced and neutral scientific environment. Furthermore, much attention will be given to clinical management through extensive clinical case discussions.